1. Home
  2. MSGY vs ENVB Comparison

MSGY vs ENVB Comparison

Compare MSGY & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MSGY

Masonglory Limited Ordinary Shares

N/A

Current Price

$4.27

Market Cap

6.0M

Sector

N/A

ML Signal

N/A

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

HOLD

Current Price

$1.52

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSGY
ENVB
Founded
2018
1994
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0M
6.7M
IPO Year
2024
2000

Fundamental Metrics

Financial Performance
Metric
MSGY
ENVB
Price
$4.27
$1.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 3.2M
63.3K
Earning Date
07-30-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $39,914,675.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.89
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.23
$0.57
52 Week High
$11.42
$13.25

Technical Indicators

Market Signals
Indicator
MSGY
ENVB
Relative Strength Index (RSI) 55.44 52.72
Support Level $0.85 $1.17
Resistance Level $5.88 $1.53
Average True Range (ATR) 1.62 0.09
MACD 0.09 -0.00
Stochastic Oscillator 25.39 41.77

Price Performance

Historical Comparison
MSGY
ENVB

About MSGY Masonglory Limited Ordinary Shares

Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Share on Social Networks: